Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
About Cryo-Cell International Inc. (CCEL)
Cryo-Cell International Inc., founded in 1989, is a pioneering company in the biotechnology and healthcare sectors, specializing in cellular processing and cryogenic storage. As the first cord blood bank to separate and store stem cells in 1992, Cryo-Cell has established itself as a leader in the field of regenerative medicine. The company’s mission revolves around providing families and public health organizations with cutting-edge solutions for the collection, processing, and preservation of stem cells derived from umbilical cord blood, cord tissue, and menstrual stem cells. With a global client base exceeding 270,000, Cryo-Cell is a trusted name in stem cell banking, known for its unwavering commitment to quality and innovation.
Core Business Areas
- Private Family Cord Blood Banking: Cryo-Cell offers families the opportunity to preserve stem cells from umbilical cord blood and tissue for potential future medical use. These stem cells are stored in the company’s state-of-the-art cryogenic facilities, ensuring long-term viability and accessibility.
- Public Cord Blood Banking: The company also engages in public cord blood banking, facilitating the collection and storage of stem cells for broader medical and research applications. This segment supports advancements in regenerative medicine and provides critical resources for public health initiatives.
- PrepaCyte CB Technology: Cryo-Cell manufactures and markets PrepaCyte CB, a proprietary processing technology designed to enhance the efficiency and quality of umbilical cord blood stem cell processing. This technology underscores the company’s commitment to innovation and excellence in cellular processing.
Competitive Positioning
Cryo-Cell’s competitive edge lies in its vertically integrated operations, which allow the company to maintain complete control over every step of the processing, testing, and cryopreservation process. This ensures the highest quality standards and reliability for its clients. Additionally, the company’s long-standing history and track record of 100% specimen viability upon thaw set it apart from competitors in the cord blood banking industry. By combining advanced technology with decades of experience, Cryo-Cell has positioned itself as a trusted partner in the evolving field of regenerative medicine.
Industry Context and Market Relevance
The stem cell banking industry is a vital component of the broader biotechnology and healthcare sectors, driven by advancements in regenerative medicine and personalized therapies. Cryo-Cell operates at the intersection of these trends, offering services that address the growing demand for stem cell-based treatments. Its focus on both private and public banking diversifies its revenue streams and enhances its relevance in multiple market segments. As awareness of the potential applications of stem cells continues to grow, Cryo-Cell is well-positioned to capitalize on these opportunities while navigating challenges such as regulatory compliance and competitive pressures.
Commitment to Quality and Innovation
Cryo-Cell’s dedication to quality is evident in its state-of-the-art facilities and rigorous processes. The company’s ability to ensure 100% viability of specimens upon thaw highlights its expertise and reliability. Furthermore, its investment in proprietary technologies like PrepaCyte CB demonstrates a commitment to staying at the forefront of innovation in cellular processing. These factors contribute to Cryo-Cell’s reputation as a leader in the stem cell banking industry.
Conclusion
In summary, Cryo-Cell International Inc. is a trailblazer in the field of cellular processing and cryogenic storage, offering comprehensive solutions for stem cell preservation. With a strong emphasis on quality, innovation, and customer trust, the company plays a pivotal role in advancing regenerative medicine and personalized healthcare. Its dual focus on private and public banking, coupled with its proprietary technologies, positions it as a key player in the biotechnology landscape.
Cryo-Cell International (CCEL) reported its fiscal year 2024 financial results, showing consolidated revenues of $32.0 million, up from $31.3 million in 2023. The company achieved a net income of $402,000 ($0.05 per share) in 2024, compared to a net loss of $9.5 million in 2023.
The revenue breakdown included $31.6 million in processing and storage fees, $68,000 in product revenue, and $367,000 in public banking revenue. The company faced a $2.4 million income tax expense, with $1.3 million attributed to Florida's revenue apportionment methodology change. Realized and unrealized gains on marketable securities were $1.1 million in 2024, up from $51,000 in 2023.
Cryo-Cell International (NYSE American: CCEL), the world's first private cord blood bank, has announced two significant developments. First, the company's Board of Directors has approved a quarterly cash dividend of $0.25 per share of common stock, payable on February 28, 2025, to shareholders of record as of February 14, 2025. Second, the company has paused its strategic initiatives related to potential sale or merger activities.
The Board will continue to evaluate the dividend policy regularly, though they note there is no guarantee of future dividend payments. Cryo-Cell, which pioneered stem cell separation and storage in 1992, maintains its position as a leader in cord blood banking.
Cryo-Cell International (NYSE: CCEL), the world's first private cord blood bank, has announced the initiation of a regular quarterly cash dividend of $0.25 per share. The dividend will be paid on November 29, 2024, to shareholders of record as of November 15, 2024. The Board of Directors will evaluate the dividend policy regularly, considering factors such as earnings, cash flows, and capital requirements. The company's Chairman and Co-CEO David Portnoy emphasized this as a significant step in delivering shareholder value while continuing to evaluate strategic alternatives.
Cryo-Cell International, Inc. (NYSE: CCEL), the world's first private cord blood bank, reported its fiscal third quarter 2024 financial results. Highlights include:
- Revenue increased to $8.07 million, up from $7.87 million in Q3 2023
- Net income rose to $1.05 million ($0.13 per share), compared to $681,000 ($0.08 per share) in Q3 2023
- Gains on marketable securities were $522,000, up from $93,000 in Q3 2023
The company is exploring strategic alternatives to maximize shareholder value and considering instituting a regular quarterly dividend. Cryo-Cell's proposed spinoff of Celle Corp. is currently on hold due to a Demand for Arbitration filed with Duke University. The company continues to expand its services, including the launch of ExtraVault for biostorage and distribution solutions.
Cryo-Cell International, Inc. (NYSE American: CCEL), the world's first private cord blood bank, reported its fiscal second quarter 2024 financial results. Key highlights include:
- Revenue increased 3% to $8.0 million, compared to $7.8 million in Q2 2023
- Net income rose to $656,000 ($0.08 per share), up from $221,000 ($0.03 per share) in Q2 2023
- Cost of sales decreased by 6%
- Selling, general and administrative expenses decreased by less than 1%
- R&D expenses were $241,000, down from $305,000 in Q2 2023
The company's improved performance was driven by increased processing and storage fee revenue, which offset declines in public banking revenue.
FAQ
What is the current stock price of Cryo-Cell Intl (CCEL)?
What is the market cap of Cryo-Cell Intl (CCEL)?
What does Cryo-Cell International Inc. do?
What is Cryo-Cell’s competitive advantage?
How does Cryo-Cell generate revenue?
What industries does Cryo-Cell operate in?
What is PrepaCyte CB?
Who are Cryo-Cell’s primary customers?
What makes Cryo-Cell unique in the stem cell banking industry?
How does Cryo-Cell support public health initiatives?
What role does Cryo-Cell play in regenerative medicine?
Where are Cryo-Cell’s facilities located?
